FDA Speeds Up Psychedelic Meds for Mental Health

0:00On April 24th, the FDA just dropped big news on speeding up research into psychedelic meds for mental health after President Trump's executive order. They're pushing hard to get these perception-altering treatments approved faster, targeting stuff like depression and PTSD that regular meds can't. Touch. Building on that, the agency is handing out national priority vouchers to three companies testing methalone, a synthetic stimulant kind of like MDMA-end. Silasibon, the key compound in magic mushrooms. These vouchers jumped the line for reviews on treatment-resistant depression, major depressive disorder, and post-traumatic stress. This hits home especially for veterans battling mental illness from their service. Officials say it's a direct response to the nation's mental health crisis, with health and human services secretary Robert F. Kennedy Jr. stressing. Responsible access under Trump's lead. Trump signed the order last Saturday, zeroing in on eyeball gain and other schedule one drugs that have been locked down as high risk.

1:00His big push? Giving our military heroes real options beyond the usual pills. As this ramps up, we could see these therapies hit the market sooner, offering fresh hope where it's needed most. Keep an eye on how it unfolds. Pop culture, powered by AI. This is Entertainment and Celebrity News Today.